JF Colombel, EV Loftus, WJ Tremaine, LJ … - Gastroenterology, 2004 - Elsevier : The aim of this study was to evaluate the short- and long-term safety of
infliximab in patients with Crohn's disease in clinical practice. : The medical
records of 500 consecutive patients treated with infliximab at the Mayo ... Cited by 452 - Related articles - BL Direct - All 11 versions
- ►ahajournals.org M Cesari, BWJH Penninx, AB Newman, SB … - Circulation, 2003 - Am Heart Assoc Methods and Results— The subjects were 2225 participants 70 to 79 years old,
without baseline cardiovascular disease, who were enrolled in the Health, Aging,
and Body Composition study. Incident coronary heart disease (CHD), stroke, ... Cited by 376 - Related articles - BL Direct - All 11 versions
- ►ahajournals.org DL Mann, JJV McMurray, M Packer, K Swedberg … - Circulation, 2004 - Am Heart Assoc From the Winters Center for Heart Failure Research (DLM), Baylor College of
Medicine and the Houston VA, Houston, Tex; Department of Cardiology, Western
Infirmary (JJVM), Glasgow, United Kingdom; Department of Medicine, ... Cited by 346 - Related articles - BL Direct - All 11 versions
- ►toodoc.com [PDF] F Wolfe, K Michaud - The American journal of medicine, 2004 - Elsevier Heart failure was more common among patients with rheumatoid arthritis (3.9% [n
= 461]) than in those with osteoarthritis (2.3% [n = 87]), after adjusting for
differences in demographic characteristics. Patients with rheumatoid ... Cited by 183 - Related articles - All 11 versions
LT Jacobsson, C Turesson, A Gulfe, MC … - J Rheumatol, 2005 - jrheum.org Page 1. 1213 Jacobsson, et al: TNF inhibitors and cardiovascular events
Treatment with Tumor Necrosis Factor Blockers Is Associated ... Cited by 156 - Related articles - All 9 versions
LM Aledort - Journal of Thrombosis and Haemostasis, 2004 - interscience.wiley.com Summary. Thrombosis is a rare but well-recognized potential complication of
Factor VIII Inhibitor Bypass Activity (FEIBA) infusion. Recombinant factor VIIa
(rFVIIa) is increasingly used as an alternative to FEIBA; however, the ... Cited by 129 - Related articles - BL Direct - All 9 versions
- ►bad.org.uk [PDF] CH Smith, AV Anstey, J Barker, AD Burden, … - British Journal of Dermatology, 2005 - members.medscape.com Psoriasis is a common, persistent, relapsing inflammatory skin disease that can
be associated with significant morbidity. Quality of life studies in psoriasis
reveal a negative impact on patients comparable with that seen in cancer, ... Cited by 125 - Related articles - BL Direct - All 18 versions
W Sterry, J Barker, WH Boehncke, JD Bos, S … - British Journal of Dermatology, 2004 - interscience.wiley.com Psoriasis is a chronic, immune-mediated disorder that usually requires long-term
treatment for control. Approximately 25% of patients have moderate to severe
disease and require phototherapy, systemic therapy or both. Despite the ... Cited by 123 - Related articles - All 7 versions
MC Hochberg, MG Lebwohl, SE Plevy, KF … - Seminars in arthritis and rheumatism, 2005 - Elsevier The TNF-blockers infliximab, etanercept, and adalimumab are all approved for
treatment of RA. All 3 are effective, and there are currently no published data
from head-to-head clinical trials to support using 1 agent over another. ... Cited by 111 - Related articles - All 11 versions
- ►bmj.com DE Furst, FC Breedveld, JR Kalden, JS … - British Medical Journal, 2005 - ard.bmj.com As in previous years, the consensus group to consider the use of biological
agents was constituted by rheumatologists from the universities of Erlangen,
Leiden, and Vienna in Europe in cooperation with other universities in the ... Cited by 106 - Related articles - BL Direct - All 16 versions
